Learn More
BACKGROUND Few data have evaluated physician adherence to cardiovascular disease (CVD) prevention guidelines according to physician specialty or patient characteristics, particularly gender. METHODS AND RESULTS An online study of 500 randomly selected physicians (300 primary care physicians, 100 obstetricians/gynecologists, and 100 cardiologists) used a(More)
S troke ranks as the third leading cause of death in the United States. It is now estimated that there are more than 700 000 incident strokes annually and 4.4 million stroke survivors. 1,2 The economic burden of stroke was estimated by the American Heart Association to be $51 billion (direct and indirect costs) in 1999. 3 Despite the advent of treatment of(More)
S ince the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC) consensus statement on secondary prevention (1), important evidence from clinical trials has emerged that further supports and broadens the merits of aggressive risk-reduction therapies for patients with established coronary and other atheroscle-rotic(More)
W orldwide, cardiovascular disease (CVD) is the largest single cause of death among women, accounting for one third of all deaths. 1 In many countries, including the United States, more women than men die every year of CVD, a fact largely unknown by physicians. 2,3 The public health impact of CVD in women is not related solely to the mortality rate, given(More)
BACKGROUND Stroke is the third leading cause of death in the United States and a major cause of morbidity in women. Awareness of risk may be an important first step in stroke prevention. The purpose of this study was to assess knowledge and awareness about stroke in a nationally representative sample of women. METHODS AND RESULTS An American Heart(More)
O ver the past decade, scientists, healthcare providers, the public, and policy makers have made substantial efforts to improve understanding of the sex/gender* differences in cardiovascular disease (CVD) † and to recognize the importance of heart disease in women. Federal and American Heart Association (AHA) initiatives to raise awareness and to reduce(More)
C oronary heart disease (CHD) is the single leading cause of death and a significant cause of morbidity among American women. 1 Risk factors for CHD in women are well documented. 2 Compelling data from epidemiological studies and randomized clinical trials show that CHD is largely preventable. Assessment and management of several risk factors for CHD are(More)
BACKGROUND Awareness of cardiovascular disease (CVD) risk has been linked to taking preventive action in women. The purpose of this study was to assess contemporary awareness of CVD risk and barriers to prevention in a nationally representative sample of women and to evaluate trends since 1997 from similar triennial surveys. METHODS AND RESULTS A(More)
BACKGROUND The Raloxifene Use for The Heart (RUTH) trial showed that raloxifene, a selective estrogen receptor modulator, had no overall effect on the incidence of coronary events in women with established coronary heart disease or coronary heart disease risk factors. We provide detailed results of the effect of raloxifene on coronary outcomes over time and(More)
BACKGROUND Noninvasive measures of arterial compliance may be useful for the detection of subclinical atherosclerosis. METHODS AND RESULTS Measures of calf and thigh arterial compliance (MaxV50) were recorded in 267 subjects who also underwent MRI of the distal aorta to quantify distal aorta atherosclerosis. The average of calf and thigh MaxV50 was(More)